Emerging biomarkers in head and neck cancer in the era of genomics
Top Cited Papers
- 18 November 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 12 (1), 11-26
- https://doi.org/10.1038/nrclinonc.2014.192
Abstract
Head and neck cancer (HNC) broadly includes carcinomas arising from the mucosal epithelia of the head and neck region as well as various cell types of salivary glands and the thyroid. As reflected by the multiple sites and histologies of HNC, the molecular characteristics and clinical outcomes of this disease vary widely. In this Review, we focus on established and emerging biomarkers that are most relevant to nasopharyngeal carcinoma and head and neck squamous-cell carcinoma (HNSCC), which includes primary sites in the oral cavity, oropharynx, hypopharynx and larynx. Applications and limitations of currently established biomarkers are discussed along with examples of successful biomarker development. For emerging biomarkers, preclinical or retrospective data are also described in the context of recently completed comprehensive molecular analyses of HNSCC, which provide a broad genetic landscape and molecular classification beyond histology and clinical characteristics. We will highlight the ongoing effort that will see a shift from prognostic to predictive biomarker development in HNC with the goal of delivering individualized cancer therapy.Keywords
This publication has 201 references indexed in Scilit:
- The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1British Journal of Cancer, 2013
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialThe Lancet Oncology, 2013
- Dual fluorescent molecular substrates selectively report the activation, sustainability and reversibility of cellular PKB/Akt activityScientific Reports, 2013
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After ChemoradiationInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Oncogenic activities of human papillomavirusesVirus Research, 2009
- The Relationship Between Human Papillomavirus Status and Other Molecular Prognostic Markers in Head and Neck Squamous Cell CarcinomasInternational Journal of Radiation Oncology*Biology*Physics, 2009
- The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral CancerHead and Neck Pathology, 2009
- Mdm2 promotes the rapid degradation of p53Nature, 1997